The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Surgical journey for participants (pts) in the MATTERHORN trial: A global, randomized, phase 3 study of durvalumab (D) plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric/gastroesophageal junction (G/GEJ) adenocarcinoma.
 
Daniela Molena
Honoraria - AstraZeneca; AstraZeneca; Intuitive Surgical; Johnson & Johnson/MedTech; Medela; Merck
Consulting or Advisory Role - AstraZeneca; AstraZeneca/MedImmune; Johnson & Johnson; proteomics; proteomics
Travel, Accommodations, Expenses - AstraZeneca
 
Woo Jin Hyung
Employment - Hutom
Leadership - Hutom
Stock and Other Ownership Interests - Hutom
Research Funding - GC Pharma; Medtronic
 
Zev Wainberg
Consulting or Advisory Role - Alligator Bioscience; Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bridgebio; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; EMD Serono; Ipsen; Janssen Oncology; Lilly; Merck; Merck KGaA; Novartis; Pfizer; Phanes Therapeutics; Revolution Medicines; Seagen
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Lilly; Merck
 
Moishe Liberman
Stock and Other Ownership Interests - AssistIQ, Endocision, Ditch
Consulting or Advisory Role - Merck, AstraZeneca, Sparrow, Noah Medical, J&J LCI
Research Funding - Boston Scientific, Olympus, J&J, Intuitive, Merck, Broncus, BMS, AstraZeneca, Pfizer, Roche, Novartis, POINT Biopharma, Galvanize Therapeutics, Caprion, ODS Medical (Inst)
Patents, Royalties, Other Intellectual Property - 1. Sting-Mark. 2. Intragastric Balloon System
 
Gunnar Folprecht
Consulting or Advisory Role - Amgen; AstraZeneca; BeiGene; Bristol-Myers Squibb; Daichi; GlaxoSmithKline; Incyte; Merck KGaA; Merck Sharp & Dohme; Roche/Genentech; SERVIER; Takeda
Speakers' Bureau - Abbvie; Incyte
Travel, Accommodations, Expenses - AstraZeneca; Merck Serono; Pierre Fabre; Roche; Takeda
 
Inmaculada Diaz
Consulting or Advisory Role - AstraZeneca Spain; BMSi; Merck
Speakers' Bureau - AstraZeneca Spain; BMSi; SERVIER
Travel, Accommodations, Expenses - AstraZeneca; Roche
 
Takaki Yoshikawa
Honoraria - Astellas Pharma; AstraZeneca; BMS; Chugai Pharma; Daiichi Sankyo; Intuitive Surgical; Johnson & Johnson/Janssen; Medtronic; MSD; Olympus; Ono Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/UCB Japan
Research Funding - Lilly
 
Salah-Eddin Al-Batran
Stock and Other Ownership Interests - Frankfurter Institut für Klinische Krebsforschung IKF GmbH
Consulting or Advisory Role - Bristol-Myers Squibb; Eli Lilly Germany; Merck Sharp & Dohme
Speakers' Bureau - MCI Group
Research Funding - AstraZeneca; Bristol-Myers Squibb; Celgene; Eurozyto; Federal Ministry of Education and Research; German Cancer Aid; German Research Foundation; Immutep; Ipsen; Lilly; MSD Sharp & Dohme; Roche; Sanofi; Vifor Pharma
 
Eric Van Cutsem
Consulting or Advisory Role - Abbvie; Agenus; ALX Oncology; Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Bexon Clinical Consulting; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb; Cantargia AB; Daiichi Sankyo; Debiopharm Group; Eisai; ElmediX; Fosum; Galapagos NV; GlaxoSmithKline; Ipsen; ITeos Therapeutics; Lilly; Merck KGaA; Merck Sharp & Dohme; Microbial Machines; Mirati Therapeutics; Nordic Group; Novartis; Novocure; Pfizer; Pierre Fabre; Sanofi; Seagen; SERVIER; Simcere; Taiho Pharmaceutical; Takeda; Trishula Therapeutics
 
Kei Muro
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Lilly; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Chugai Pharma; Ono Pharmaceutical
Research Funding - Amgen (Inst); Chugai Pharma (Inst); MSD (Inst); PRA Health Sciences (Inst); Taiho Pharmaceutical (Inst)
 
Peter Grimminger
No Relationships to Disclose
 
Takeshi Omori
Speakers' Bureau - Bristol-Myers Squibb Japan; Johnson & Johnson/MedTech; Medtronic; Ono Pharmaceutical
 
Miguel Sotelo Lezama
No Relationships to Disclose
 
István Sipocz
No Relationships to Disclose
 
Myriam Chalabi
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene (Inst); MSD (Inst); Roche/Genentech
Research Funding - Agenus (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Lin-Yang Cheng
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Eric Heilbron
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Scott Robbins
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Yelena Janjigian
Stock and Other Ownership Interests - Inspirna; OncoDaily; Veda Life Sciences
Honoraria - Abbvie; AmerisourceBergen; Arcus Biosciences; AskGene Pharma; Astellas Pharma; AstraZeneca; Basilea Pharmaceutical; Bayer; BeOne; Boehringer Ingelheim; Bristol-Myers Squibb; Clinical Care Options; Daiichi Sankyo; eChinaHealth; Ed Med Resources (OncInfo); Eisai; Geneos; Genzyme; Gilead Sciences; GlaxoSmithKline; Guardant Health; H.C. Wainwright & Co.; HMP Education; i3 Health; i3 Health; IDEOlogy Health; Imedex; Imugene; Inspirna; Lilly; Lynx Health; Master Clinician Alliance; Merck; Merck Serono; Mersana; Michael J. Hennessy Associates; Paradigm; Peerview; Pfizer; Physicians' Education Resource, LLC; Regeneron; Research to Practice; Seagen; Silverback Therapeutics; Suzhou Liangyihui Network Technology; Talem Health; TotalCME; WebMD; Zymeworks
Consulting or Advisory Role - Abbvie; AmerisourceBergen; Arcus Biosciences; AskGene Pharma; Astellas Pharma; AstraZeneca; Basilea Pharmaceutical; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Clinical Care Options; Daiichi Sankyo; Debbies Dream Foundation; Ed Med Resources (OncLive); Eisai; Geneos; Genzyme; GlaxoSmithKline; GlaxoSmithKline; Guardant Health; H.C. Wainwright & Co.; HMP Education; Imedex; Imugene; Inspirna; Jazz Pharmaceuticals; Lilly; Lynx Health; Merck; Merck Serono; Mersana; Michael J. Hennessy Associates; OncoDaily; Paradigm; Peerview; Pfizer; Physicians' Education Resource, LLC; Research to Practice; Seagen; Signatera; Silverback Therapeutics; WebMD; Zymeworks
Research Funding - Arcus Biosciences (Inst); Astellas Pharma; AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Cycle for Survival (Inst); Department of Defense (Inst); Fred's Team (Inst); Genentech/Roche (Inst); Inspirna (Inst); Lilly (Inst); Merck (Inst); NCI (Inst); Stand up to Cancer (Inst); Transcenta (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb Japan; Merck
Other Relationship - Axis Medical Education; Clinical Care Options; Giants of Cancer Care; Research to Practice
 
Josep Tabernero
Stock and Other Ownership Interests - 1TRIALSP; Alentis Therapeutics; Oniria Therapeutics; Pangaea Oncology
Consulting or Advisory Role - Accent Therapeutics; Alentis Therapeutics; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Carina Biotech; Cartography Biosciences; Chugai Pharma; Daiichi Sankyo; F. Hoffmann LaRoche; Genentech; Johnson & Johnson/Janssen; Larkspur Biosciences Inc; Lilly; Marengo Therapeutics; Menarini; Merus; MSD; Novartis; Ono Pharmaceutical; Peptomyc; Pfizer; Pierre Fabre; Quantro Therapeutics; Scandion Oncology; Scorpion Therapeutics; Servier; Sotio; Syntelios AG; Taiho Pharmaceutical; Takeda Pharmaceuticals International AG; Tolremo